Macrophage-derived biomimetic nanoparticles for light-driven theranostics toward Mpox

Wang, Wei; Li, Bin; Wu, Yunxia; Li, Mengjun; Ma, Shengchao; Yan, Dingyuan; Li, Dan; Zhang, Jie; Li, Xiaoxue; Gao, Qiuxia; Zhao, Lu; Hu, Ziwei; Jiang, Yushan; Liu, Zining; Liu, Ke; Yan, Yan; Feng, Yi; Zheng, Judun; Shu, Bowen; Wang, Jiamei; Wang, Huanhuan; He, Lingjie; Zhou, Sitong; Wang, Dong; Shen, Chenguang; Tang, Ben Zhong; Liao, Yuhui

doi:10.1016/j.matt.2024.01.004

Cited by 23 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As enzyme activity and blood glucose concentrations are strongly correlated with each other, the inhibition of α-glucosidase can potentially decrease postprandial blood glucose levels 10 , 11 . The function of α-glucosidase inhibitors like acarbose, miglitol, and voglibose, used in clinical settings is to slow down sharp rises in blood sugar levels 12 , 13 . The α-glucosidase enzyme found in human intestinal cells serves a crucial role as the primary hydrolase enzyme.…”

Section: Introductionmentioning

confidence: 99%

Design, synthesis, molecular docking study, and α-glucosidase inhibitory evaluation of novel hydrazide–hydrazone derivatives of 3,4-dihydroxyphenylacetic acid

Khan,

Jan,

Shakoor

et al. 2024

Sci Rep

View full text Add to dashboard Cite

A series of novel Schiff base derivatives (1–28) of 3,4-dihydroxyphenylacetic acid were synthesized in a multi-step reaction. All the synthesized Schiff bases were obtained in high yields and their structures were determined by 1HNMR, 13CNMR, and HR-ESI–MS spectroscopy. Except for compounds 22, 26, 27, and 28, all derivatives show excellent to moderate α-glucosidase inhibition. Compounds 5 (IC50 = 12.84 ± 0.52 µM), 4 (IC50 = 13.64 ± 0.58 µM), 12 (IC50 = 15.73 ± 0.71 µM), 13 (IC50 = 16.62 ± 0.47 µM), 15 (IC50 = 17.40 ± 0.74 µM), 3 (IC50 = 18.45 ± 1.21 µM), 7 (IC50 = 19.68 ± 0.82 µM), and 2 (IC50 = 20.35 ± 1.27 µM) shows outstanding inhibition as compared to standard acarbose (IC50 = 873.34 ± 1.67 µM). Furthermore, a docking study was performed to find out the interaction between the enzyme and the most active compounds. With this research work, 3,4-dihydroxyphenylacetic acid Schiff base derivatives have been introduced as a potential class of α-glucosidase inhibitors that have remained elusive till now.

show abstract

Section: Introductionmentioning

confidence: 99%

Design, synthesis, molecular docking study, and α-glucosidase inhibitory evaluation of novel hydrazide–hydrazone derivatives of 3,4-dihydroxyphenylacetic acid

Khan,

Jan,

Shakoor

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Notably, macrophage CM (MCM) coatings have shown exceptional ability in recognizing pathogens such as viruses, bacteria, and fungi, thereby enhancing the effectiveness of nanotherapeutics against a range of pathogens. 5 In their study, the authors innovatively employed pre-activated membranes (PMs) from M. marinum -treated RAW 264.7 macrophage cells, exhibiting high levels of TB-specific receptors. By wrapping TPE-BT-BBTD-containing PLGA NPs with these PMs, they fabricated BBTD@PM NPs.…”

mentioning

confidence: 99%

Pre-activated macrophage membrane-encased aggregation-induced emission featuring nanoparticles: a novel possibility for tuberculosis treatment

Cai,

Tian,

Shubhra

2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

Extracellular Vesicle‐Inspired Therapeutic Strategies for the COVID‐19

Hu,

Wang,

Lin

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Emerging infectious diseases like coronavirus pneumonia (COVID‐19) present significant challenges to global health, extensively affecting both human society and the economy. Extracellular vesicles (EVs) have demonstrated remarkable potential as crucial biomedical tools for COVID‐19 diagnosis and treatment. However, due to limitations in the performance and titer of natural vesicles, their clinical use remains limited. Nonetheless, EV‐inspired strategies are gaining increasing attention. Notably, biomimetic vesicles, inspired by EVs, possess specific receptors that can act as “Trojan horses,” preventing the virus from infecting host cells. Genetic engineering can enhance these vesicles by enabling them to carry more receptors, significantly increasing their specificity for absorbing the novel coronavirus. Additionally, biomimetic vesicles inherit numerous cytokine receptors from parent cells, allowing them to effectively mitigate the “cytokine storm” by adsorbing pro‐inflammatory cytokines. Overall, this EV‐inspired strategy offers new avenues for the treatment of emerging infectious diseases. Herein, this review systematically summarizes the current applications of EV‐inspired strategies in the diagnosis and treatment of COVID‐19. The current status and challenges associated with the clinical implementation of EV‐inspired strategies are also discussed. The goal of this review is to provide new insights into the design of EV‐inspired strategies and expand their application in combating emerging infectious diseases.

show abstract

Macrophage-derived biomimetic nanoparticles for light-driven theranostics toward Mpox

Cited by 23 publications

References 42 publications

Design, synthesis, molecular docking study, and α-glucosidase inhibitory evaluation of novel hydrazide–hydrazone derivatives of 3,4-dihydroxyphenylacetic acid

Design, synthesis, molecular docking study, and α-glucosidase inhibitory evaluation of novel hydrazide–hydrazone derivatives of 3,4-dihydroxyphenylacetic acid

Pre-activated macrophage membrane-encased aggregation-induced emission featuring nanoparticles: a novel possibility for tuberculosis treatment

Extracellular Vesicle‐Inspired Therapeutic Strategies for the COVID‐19

Contact Info

Product

Resources

About